2023
“Cancer’s a demon”: a qualitative study of fear and multilevel factors contributing to cancer treatment delays
Frosch Z, Jacobs L, O’Brien C, Brecher A, McKeown C, Lynch S, Geynisman D, Hall M, Edelman M, Bleicher R, Fang C. “Cancer’s a demon”: a qualitative study of fear and multilevel factors contributing to cancer treatment delays. Supportive Care In Cancer 2023, 32: 13. PMID: 38060063, DOI: 10.1007/s00520-023-08200-9.Peer-Reviewed Original ResearchPsychological distressPsychological sourcesPsychological factorsPsychological onesPsychological barriersQualitative studyTeam membersTreatment delayDistressCancer treatment delayHalf of patientsResultsTwenty-two patientsStart of therapyFearCommon solid tumorsCancer therapyCare team membersAnticipatory guidanceBeliefsMultilevel factorsPatients' beliefsMultiple aspectsCancer careCurrent guidelinesCare team
2022
Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers.
Malhotra J, Philip E, Govindarajan A, Meza L, Zengin Z, Salgia S, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 328-328. DOI: 10.1200/jco.2022.40.6_suppl.328.Peer-Reviewed Original ResearchAdvanced genitourinary cancersGenitourinary cancersExpectation of cureQuality of lifeSide effectsMetastatic genitourinary cancerProportion of patientsStart of therapyMajority of patientsMonths of treatmentRenal cell carcinomaSevere side effectsLongitudinal studyMedian ageClinical outcomesImmunotherapy treatmentCell carcinomaPatients' perceptionsImmunotherapyPatientsGreater efficacyTumor progressionCancerCancer treatmentTime points
2021
Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States
Zeidan A, Pollyea D, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Bonifacio G, Chen C. Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States. Blood 2021, 138: 277. DOI: 10.1182/blood-2021-147926.Peer-Reviewed Original ResearchClinical Trials CommitteeRelapse-free survivalAcute myeloid leukemiaMedian relapse-free survivalCurrent equity holderElectronic medical record databaseBristol-Myers SquibbSubgroups of ptsIntensive chemotherapyIC cohortStart of therapyOverall survivalTrials CommitteeMedical record databaseRemission rateCR rateAge-based subgroupsYears subgroupRecord databaseIncomplete hematologic recovery (CRi) ratesReal-world clinical practicePhase 3 trial dataAdvisory CommitteeDaiichi SankyoGood remission rate
2020
175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)
Williams D, Creech C, Walter E, Martin J, Gerber J, Newland J, Howard L, Hofto M, Staat M, Oler R, Conrad T, Tuyishimire B, Pettigrew M, Fowler V, Chambers H, Zaoutis T, Evans S, Huskins W. 175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP). Open Forum Infectious Diseases 2020, 7: s216-s216. PMCID: PMC7776421, DOI: 10.1093/ofid/ofaa439.485.Peer-Reviewed Original ResearchShort-course therapyCourse therapyAntibiotic exposureClinical improvementOutpatient therapyAdverse effectsDouble-blind Controlled TrialPlacebo-controlled superiority trialDays of antibioticsInitial clinical improvementShort antibiotic exposureShorter antibiotic coursesCommunity-acquired pneumoniaStart of therapyCAP treatmentChildren ages 6Antibiotic coursesInitial therapyAcquired PneumoniaBaseline characteristicsClinical responseSecondary outcomesStandard therapyControlled TrialsPrimary outcome
2018
Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Erradication
Vinaixa C, Belli L, Berenguer M, Cortesi P, Strazzabosco M, Faccheti R, Rockenschaub S, Martini S, Morelli C, Donato F, Volpes R, Pasulo L, Pageaux G, Coilly A, Perricone G, Mazzarelli C, Di Nicola S, Berlakovich G, Duvuox C. Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Erradication. Transplantation 2018, 102: s3. DOI: 10.1097/01.tp.0000542536.91165.49.Peer-Reviewed Original ResearchDirect acting antiviralsMedian Child-PughHepatocellular carcinomaChild-PughMedian followLiver transplantationMELD scoreClinical improvementSecond generation direct acting antiviralsClinical outcome 2 yearsDevelopment of HCCIntestine Transplant AssociationChronic HCV infectionLiver transplant candidatesLiver function testsStart of therapySignificant clinical improvementRisk of deathOutcomes 2 yearsDAA therapyEuropean LiverDecompensated cirrhosisHCV infectionAbdominal ultrasoundActing antivirals
2011
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis
Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der PouwKraan T, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, Verweij CL. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis. Genes & Immunity 2011, 12: 466-472. PMID: 21471993, DOI: 10.1038/gene.2011.18.Peer-Reviewed Original ResearchConceptsRelapsing-remitting multiple sclerosisNon-responder statusInterferon regulatory factor 5IFNβ treatmentMultiple sclerosisT2 lesionsClinical outcomesMore magnetic resonance imagingMore T2 lesionsStart of therapyGene variantsInterferon-β TherapyIFN response genesRegulatory factor 5Poor pharmacological responseMagnetic resonance imagingIFNβ therapyClinical responseFirst relapseIndependent cohortPharmacological responseClinical relevanceG allelePatientsResonance imaging
2007
Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?
Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? Journal Of Surgical Oncology 2007, 96: 474-480. PMID: 17640031, DOI: 10.1002/jso.20856.Peer-Reviewed Original ResearchConceptsNeoadjuvant therapyNeoadjuvant chemotherapyPreoperative chemotherapyTumor sizePhysical examBreast cancerFinal pathologic tumor sizePathologic tumor sizeStart of therapyInvasive breast cancerBreast cancer patientsPathologic tumor responseCorrelation of ultrasoundUse of MRIPhysical exam dataComplete respondersBreast conservationPathologic sizeCancer patientsPathology sizeTumor responseUS assessmentPathologic measurementsPathology responsePatients
2002
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O’Reilly M, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. Journal Of Clinical Oncology 2002, 20: 3804-14. PMID: 12228200, DOI: 10.1200/jco.2002.05.102.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAngiogenesis InhibitorsApoptosisBiomarkersCD3 ComplexCollagenDose-Response Relationship, DrugEndostatinsEndotheliumFemaleFluorodeoxyglucose F18HumansIn Situ Nick-End LabelingLasersMaleMiddle AgedNeoplasmsNeovascularization, PathologicPeptide FragmentsProspective StudiesRecombinant ProteinsTomography, Emission-ComputedConceptsTumor blood flowRh-EndoTumor cell apoptosisPositron emission tomographyBlood flowEndothelial cell apoptosisCell apoptosisClinical trialsAntiangiogenic therapyEndothelial cellsWeeks of therapyStart of therapyDose-finding clinical trialsRecombinant human endostatinHuman recombinant endostatinTreatment of cancerBiologic markersAntiangiogenic treatmentBiopsy specimensAppropriate dosePET scansBiopsy analysisHuman endostatinTherapyTumor tissue
2000
Atovaquone and Azithromycin for the Treatment of Babesiosis
Krause P, Lepore T, Sikand V, Gadbaw J, Burke G, Telford S, Brassard P, Pearl D, Azlanzadeh J, Christianson D, McGrath D, Spielman A. Atovaquone and Azithromycin for the Treatment of Babesiosis. New England Journal Of Medicine 2000, 343: 1454-1458. PMID: 11078770, DOI: 10.1056/nejm200011163432004.Peer-Reviewed Original ResearchConceptsCommon adverse effectsTreatment of babesiosisAdverse reactionsAdverse effectsCourse of clindamycinRegimen of clindamycinStart of therapyMalaria-like illnessPromising alternative treatmentStandard treatmentAlternative treatmentRegimenClindamycinAzithromycinAtovaquoneMonthsDiarrheaTreatmentBabesiosisQuinineSymptomsSubjectsPercentDaysBabesia microti DNA9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors
Mullani N, Herbst R, Abbruzzese J, Charnsangavej C, Kim E, Tran H, Barron B, Lamki L, Gould K. 9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors. Molecular Imaging And Biology 2000, 3: 151. PMID: 11150754, DOI: 10.1016/s1095-0397(00)00063-7.Peer-Reviewed Original ResearchStandard uptake valueTumor blood flowBlood flowGlucose metabolismImaged tumorsTumor-bearing sitesStart of therapyTumor metabolic activityRegional blood flowNovel antiangiogenic agentsDays of treatmentNon-invasive imagingAntiangiogenic treatmentAntiangiogenic agentsPatientsDose levelsUptake valueTumorsHuman tumorsPercentage changePhase IOxygen-15Flourine-18TreatmentDose
1997
Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
Rezza G, Galai N, Pezzotti P, Vlahov D, Graham N, Viale P, Angarano G. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study. Antiviral Therapy 1997, 2: 167-74. PMID: 11322271.Peer-Reviewed Original ResearchConceptsCD4 cell countInitiation of treatmentZidovudine monotherapyP24 antigenaemiaCell countConstitutional symptomsHIV seroconvertersRisk groupsCopies/Human immunodeficiency virus seroconvertersPlasma RNA viral loadHIV RNA copiesCD4 cell declineRNA viral loadStart of therapyMarker of responseAntigen-positive individualsAdditional predictive informationIndicator of responseStandard survival methodsTerms of progressionAntiretroviral therapyViral loadAntigen levelsDisease progression
1985
Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer.
Johnson B, Becker B, Goff W, Petronas N, Krehbiel M, Makuch R, McKenna G, Glatstein E, Ihde D. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. Journal Of Clinical Oncology 1985, 3: 1659-67. PMID: 2999346, DOI: 10.1200/jco.1985.3.12.1659.Peer-Reviewed Original ResearchConceptsProphylactic cranial irradiationMental status examinationLarge radiotherapy fractionsCranial irradiationStatus ExaminationScan abnormalitiesNeuropsychologic testingSmall-cell lung cancer trialHigh-dose induction chemotherapyLow-dose maintenance chemotherapySmall cell lung cancerRadiotherapy fractionsAbnormal neurologic examinationCranial tomography scanProgressive ventricular dilatationTherapeutic cranial irradiationTomography scan abnormalitiesHigh-dose chemotherapyStart of therapyLong-term survivorsLung cancer trialsMajority of casesCCT findingsInduction chemotherapyMaintenance chemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply